Trial Profile
A Phase Ib/ II Study of Sorafenib and Pembrolizumab in Advanced Hepatocellular Cancer (HCC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 02 Jan 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 27 Dec 2023 Planned End Date changed from 7 Dec 2023 to 7 Jun 2024.
- 23 Oct 2023 Planned End Date changed from 7 Oct 2023 to 7 Dec 2023.
- 17 Jul 2023 Planned End Date changed from 7 Jun 2023 to 7 Oct 2023.